Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Last Years Numbers to beat.

<< Previous

Bullboard Posts

Next >>

Post by wofatson May 10, 2023 11:59am

236 Views

Post# 35440877

Last Years Numbers to beat.

These are the results for 1st quarter last year .

These are the numbers that they should beat .

They have 150 million still in the bank and they will need to raise capital at some point .

Financial Results Last Year First Quarter
- Revenues were $63,807, an increase of $17,738 or 39% over the same period in prior year.
- Gross margin of $32,477 or 51% compared to $20,580 or 45% in the same period in prior year.
- Adjusted EBITDA1 was $13,312, an increase of $7,732 or 139% over the same period in prior year.
- Net loss on financial assets measured at fair value through profit or loss of $16,363, of which $16,281 was unrealized.
- Net loss was $18,811, compared to net income of $3,558 in the same period in prior year.
- Cash inflow from operations was $12,879, compared to a cash inflow from operations of $17,207 in the same period in prior year.
  
  Is this the same as G2S2 Capital or someone new with a large position?
  
  Medici Strategic Portfolio Management Inc. manages 11,506,844 common shares of the reporting issuer for the portfolios of its clients under discretionary management agreements, which represents approximately 10.46% of the outstanding shares of the reporting issuer.